Efficacy of HX008 in high microsatellite instability/mismatch repair–defificient (MSI-H/dMMR) solid tumors: Results from a multicenter phase II open-label study.
Jing Huang(Chinese Academy of Medical Sciences & Peking Union Medical College), Shengmian Li(Hebei Medical University), Yongqian Shu(Jiangsu Province Hospital), Xiaoge Kou(First Affiliated Hospital of Xinxiang Medical University), Zhihui Liu(Jilin University), Shu Zhang(Tianjin University of Technology), Xiaodong Zhu(Fudan University Shanghai Cancer Center), Hui Wang(Sun Yat-sen University), Xinjun Liang(Hubei Provincial Center for Disease Control and Prevention), Fen Wang(Texas A&M Health Science Center), Jingdong Zhang(Liaoning Cancer Hospital & Institute), Qingxia Fan(First Affiliated Hospital of Zhengzhou University), Yan Song(Shandong Eye Hospital), Yifu He(Anhui Provincial Hospital), Xianli Yin(Central South University), Suxia Luo(Zhengzhou University), Yunpeng Liu(Shenyang Institute of Automation), Enxiao Li(First Affiliated Hospital of Xi'an Jiaotong University), Nong Xu(First Affiliated Hospital Zhejiang University), Zhixiang Zhuang(Soochow University)
Cited by 5
Related Papers
Randomized, Double-Blind, Placebo-Controlled Phase III Trial of Apatinib in Patients With Chemotherapy-Refractory Advanced or Metastatic Adenocarcinoma of the Stomach or Gastroesophageal Junction
|Journal of Clinical Oncology|2016|1k
Camrelizumab in Combination with Apatinib in Patients with Advanced Hepatocellular Carcinoma (RESCUE): A Nonrandomized, Open-label, Phase II Trial
|Clinical Cancer Research|2020|576